Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap Down – Time to Sell?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares gapped down prior to trading on Thursday . The stock had previously closed at $5.04, but opened at $4.28. Ironwood Pharmaceuticals shares last traded at $4.65, with a volume of 175,590 shares traded.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th. Leerink Partners initiated coverage on Ironwood Pharmaceuticals in a research report on Monday, September 9th. They set a “market perform” rating and a $5.00 target price on the stock. Wells Fargo & Company lowered their price target on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, August 9th. Craig Hallum cut their price objective on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Finally, StockNews.com upgraded shares of Ironwood Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Ironwood Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.17.

Ironwood Pharmaceuticals Trading Down 7.5 %

The firm has a 50-day moving average price of $4.33 and a 200-day moving average price of $5.64. The stock has a market capitalization of $744.39 million, a PE ratio of 115.25 and a beta of 0.47.

Insiders Place Their Bets

In other news, insider Minardo John sold 9,910 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $4.27, for a total transaction of $42,315.70. Following the completion of the sale, the insider now owns 284,661 shares in the company, valued at $1,215,502.47. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 12.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Royce & Associates LP lifted its position in shares of Ironwood Pharmaceuticals by 10.8% during the 3rd quarter. Royce & Associates LP now owns 662,934 shares of the biotechnology company’s stock valued at $2,731,000 after buying an additional 64,353 shares during the last quarter. KBC Group NV lifted its position in shares of Ironwood Pharmaceuticals by 59.3% during the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 3,198 shares during the last quarter. GSA Capital Partners LLP lifted its position in shares of Ironwood Pharmaceuticals by 194.9% during the 3rd quarter. GSA Capital Partners LLP now owns 351,193 shares of the biotechnology company’s stock valued at $1,447,000 after buying an additional 232,087 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its position in shares of Ironwood Pharmaceuticals by 1,293.6% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 380,960 shares of the biotechnology company’s stock valued at $1,570,000 after buying an additional 353,624 shares during the last quarter. Finally, Harbor Capital Advisors Inc. lifted its holdings in Ironwood Pharmaceuticals by 50.1% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 168,071 shares of the biotechnology company’s stock worth $692,000 after purchasing an additional 56,097 shares in the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.